BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32699985)

  • 1. Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients.
    Sesé M; Somoza R; Maestu I; Ureste MM; Sanchez A; Cordoba JF; Sansano I; Venturas G; Ramón Y Cajal S; Hernández-Losa J
    Oncol Ther; 2019 Dec; 7(2):131-139. PubMed ID: 32699985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes.
    May T; Clement MS; Halait H; Kohlmann A; Kohlmann M; Lai J; Lee N; Li-Sucholeiki X; Meldgaard P; Joshi S; Scudder S; Shrestha N; Sorensen B; Kiral M; O'Donnell P
    PLoS One; 2024; 19(4):e0295987. PubMed ID: 38593164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing.
    Medina Diaz I; Nocon A; Mehnert DH; Fredebohm J; Diehl F; Holtrup F
    PLoS One; 2016; 11(11):e0166354. PubMed ID: 27832189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis].
    Su F; Zheng K; Fu Y; Wu Q; Tang Y; Wang W; Jiang L
    Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):389-396. PubMed ID: 29764589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.
    Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L
    Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice.
    González de Aledo-Castillo JM; Arcocha A; Victoria I; Martinez-Puchol AI; Sánchez C; Jares P; Rodríguez GF; Viñolas N; Reyes R; Reguart N; Puig-Butillé JA
    J Thorac Dis; 2021 Mar; 13(3):1658-1670. PubMed ID: 33841957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients.
    Liu HE; Vuppalapaty M; Wilkerson C; Renier C; Chiu M; Lemaire C; Che J; Matsumoto M; Carroll J; Crouse S; Hanft VR; Jeffrey SS; Di Carlo D; Garon EB; Goldman J; Sollier E
    Front Oncol; 2020; 10():572895. PubMed ID: 33117705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening system for epidermal growth factor receptor mutation detection in cytology cell-free DNA of cerebrospinal fluid based on assured sample quality.
    Kawahara A; Abe H; Murata K; Ishii H; Azuma K; Takase Y; Hattori S; Naito Y; Akiba J
    Cytopathology; 2019 Mar; 30(2):144-149. PubMed ID: 30471155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-Analytical Evaluation of Streck Cell-Free DNA Blood Collection Tubes for Liquid Profiling in Oncology.
    Diaz IM; Nocon A; Held SAE; Kobilay M; Skowasch D; Bronkhorst AJ; Ungerer V; Fredebohm J; Diehl F; Holdenrieder S; Holtrup F
    Diagnostics (Basel); 2023 Mar; 13(7):. PubMed ID: 37046506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
    Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
    JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Loss of Heterozygosity in cfDNA of Advanced
    Boldrin E; Nardo G; Zulato E; Bonanno L; Polo V; Frega S; Pavan A; Indraccolo S; Saggioro D
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
    Demuth C; Madsen AT; Weber B; Wu L; Meldgaard P; Sorensen BS
    BMC Cancer; 2018 Feb; 18(1):191. PubMed ID: 29448920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.
    Malapelle U; Sirera R; Jantus-Lewintre E; Reclusa P; Calabuig-Fariñas S; Blasco A; Pisapia P; Rolfo C; Camps C
    Expert Rev Mol Diagn; 2017 Mar; 17(3):209-215. PubMed ID: 28129709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Dynamic Use of
    Macías M; Alegre E; Alkorta-Aranburu G; Patiño-García A; Mateos B; Andueza MP; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; González Á
    Dis Markers; 2019; 2019():7954921. PubMed ID: 30809319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development, validation, and comparison of gene analysis methods for detecting
    Hanibuchi M; Kanoh A; Kuramoto T; Saito T; Tobiume M; Saijo A; Kozai H; Kondo M; Morizumi S; Yoneda H; Kagawa K; Ogino H; Sato S; Kawano H; Otsuka K; Toyoda Y; Nokihara H; Goto H; Nishioka Y
    Oncotarget; 2019 Jun; 10(38):3654-3666. PubMed ID: 31217900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid.
    Park S; Hur JY; Lee KY; Lee JC; Rho JK; Shin SH; Choi CM
    Clin Chem Lab Med; 2017 Aug; 55(10):1489-1495. PubMed ID: 28195541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR.
    Zhang Y; Xu Y; Zhong W; Zhao J; Chen M; Zhang L; Li L; Wang M
    Oncotarget; 2017 Jan; 8(4):5861-5873. PubMed ID: 28052016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
    Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
    Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance comparison of blood collection tubes as liquid biopsy storage system for minimizing cfDNA contamination from genomic DNA.
    Zhao Y; Li Y; Chen P; Li S; Luo J; Xia H
    J Clin Lab Anal; 2019 Feb; 33(2):e22670. PubMed ID: 30191594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid point-of-care testing for epidermal growth factor receptor gene mutations in patients with lung cancer using cell-free DNA from cytology specimen supernatants.
    Asaka S; Yoshizawa A; Saito K; Kobayashi Y; Yamamoto H; Negishi T; Nakata R; Matsuda K; Yamaguchi A; Honda T
    Int J Oncol; 2018 Jun; 52(6):2110-2118. PubMed ID: 29620164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.